Boston Scientific (NYSE:BSX) Hits New 52-Week Low – Should You Sell?

Boston Scientific Corporation (NYSE:BSX) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $69.52 and last traded at $71.8760, with a volume of 11649572 shares changing hands. The stock had previously closed at $71.35.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup cut its price target on BSX from $102 to $94 but kept a “buy” rating — signaling the firm still sees meaningful upside even after lowering near-term expectations. This preserves analyst support that can limit downside pressure. Citigroup Lowers PT
• Neutral Sentiment: Unusually large volume of put-option purchases was reported, indicating traders are hedging or speculating on further downside; this raises short‑term volatility but can reflect transient positioning rather than a change in fundamentals. Put Options Flow
• Negative Sentiment: Multiple law firms have filed or announced investigations and class actions against Boston Scientific covering purchases between July 23, 2025 and Feb 3, 2026; plaintiffs allege securities-law violations. A growing wave of litigation increases legal risk, potential discovery costs, and an overhang that often weighs on shares. Bronstein Class Action
• Negative Sentiment: Numerous plaintiff firms (including Rosen, Faruqi, RGRD, Bragar Eagel & Squire, and others) are soliciting lead-plaintiff motions and reminding shareholders of the May 4, 2026 deadline — amplifying publicity and the probability of consolidated litigation. That sustained media/legal attention typically pressures near-term sentiment and can increase legal-cost uncertainty. Deadline Reminder

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BSX shares. Morgan Stanley cut their price objective on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Argus upgraded Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. UBS Group reduced their price target on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Finally, Truist Financial decreased their price objective on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.00.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a 50 day simple moving average of $83.51 and a 200-day simple moving average of $93.81. The stock has a market capitalization of $103.24 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the company earned $0.70 EPS. The firm’s quarterly revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

A number of institutional investors have recently modified their holdings of the business. Steph & Co. purchased a new stake in shares of Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $26,000. Finally, Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter worth about $26,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.